2.54

0.78% -0.02

Pre-market: 2.54

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is traded at $2.54, with a volume of 458.50K. It is down -0.78% in the last 24 hours and up +9.01% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Previous Close:

$2.56

Open:

$2.56

24h Volume:

458.50K

Relative Volume:

0.69

Market Cap:

$198.20M

Revenue:

$63.63M

Net Income/Loss:

$10.62M

P/E Ratio:

50.80

EPS:

0.05

Net Cash Flow:

$-8.64M

1W Performance:

+0.40%

1M Performance:

+9.01%

6M Performance:

+141.90%

1Y Performance:

+103.20%

1-Day Range:

$2.50

$2.585

1-Week Range:

$2.43

$2.62

52-Week Range:

$0.8214

$2.76

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1165)

Industry

Biotechnology (681)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2025-03-17

Latest SEC Filings

PLX's Discussions on Twitter

Compare PLX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLX Protalix BioTherapeutics Inc.	2.54	198.20M	63.63M	10.62M	-8.64M	0.05
VRTX Vertex Pharmaceuticals Inc	484.74	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	617.00	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	567.09	34.59B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.76	33.10B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	271.04	29.15B	3.81B	-644.79M	-669.77M	-6.24

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Apr 01, 2025

Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World

Apr 01, 2025

Mar 26, 2025

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Mar 26, 2025

Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news

Mar 26, 2025

Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st

Mar 26, 2025

Mar 24, 2025

Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive Investors

Mar 24, 2025

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Nasdaq

Mar 24, 2025

Mar 22, 2025

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey

Mar 22, 2025

What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - The AM Reporter

Mar 22, 2025

Mar 21, 2025

Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors

Mar 21, 2025

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive Investors USA

Mar 21, 2025

FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World

Mar 21, 2025

Mar 20, 2025

Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World

Mar 20, 2025

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com

Mar 20, 2025

Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK

Mar 18, 2025

Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA

Mar 18, 2025

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news

Mar 18, 2025

Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com

Mar 18, 2025

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK

Mar 18, 2025

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

PLX: 2024 Results - Yahoo Finance

Mar 18, 2025